Telix Appoints David Gill as Non-Executive Director

Gill brings deep expertise in capital markets, scaling businesses, governance and corporate turn-around strategy

Apr. 2, 2026 at 7:23am

Got story updates? Submit your updates here. ›

Telix Pharmaceuticals Limited, a global biopharmaceutical company, has announced the appointment of David Gill as a Non-Executive Director (NED) as part of its Board expansion and succession planning. Gill is a life sciences executive with over 35 years of experience in senior general management and financial leadership roles across the industry.

Why it matters

Telix is a dual-listed company on the Australian Securities Exchange (ASX) and Nasdaq Global Select Market, and the appointment of Gill is expected to strengthen the Board's expertise in capital markets, governance, and corporate strategy as the company continues to grow.

The details

Gill is expected to be appointed as Chair in due course, succeeding Dr. Mark Nelson who will remain on the Board as a NED. Gill currently serves on the boards of several life sciences companies and has held CFO and President roles at publicly traded firms, bringing deep expertise in areas like scaling businesses, corporate turnarounds, and U.S. capital markets.

  • Gill's appointment is effective May 11, 2026.

The players

David Gill

A life sciences executive with over 35 years' experience in senior general management and financial leadership roles across commercial and clinical-stage biopharmaceutical (including radiopharmaceuticals) and medical device companies.

Mark Nelson

Telix's Interim Chair, who will remain on the Board as a Non-Executive Director after Gill's appointment as Chair.

Telix Pharmaceuticals Limited

A global biopharmaceutical company focused on the development and commercialization of radiopharmaceuticals to address significant unmet medical needs in oncology and rare diseases.

Got photos? Submit your photos here. ›

What they’re saying

“We are pleased to welcome David to the Board, where his strong financial expertise and deep knowledge of U.S. capital markets will be highly valuable. We intend to further strengthen the Board through additional appointments aligned with our growth trajectory and governance needs as a dual-listed company.”

— Mark Nelson, Telix Interim Chair

What’s next

Gill is expected to be appointed as Chair of Telix's Board in due course, succeeding Dr. Mark Nelson who will remain on the Board as a Non-Executive Director.

The takeaway

Telix's appointment of David Gill, an experienced life sciences executive, to its Board of Directors is a strategic move to bolster the company's expertise in capital markets, governance, and corporate strategy as it continues to grow as a dual-listed global biopharmaceutical firm.